Compare BridgeBio Pharma Inc (BBIO) vs Manchester United PLC (MANU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Manchester United PLC — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Manchester United PLC trades at $22.23 (market cap $3.74B). The key difference: BridgeBio Pharma Inc is far larger — about 4.4× Manchester United PLC's market cap, and Manchester United PLC pays a 1.26% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | MANU | |
|---|---|---|
Market Cap | $16.61B | $3.74B |
Sector | Health | Media |
52-Week High | $90.17 | $23.53 |
52-Week Low | $47.29 | $15.10 |
Enterprise Value | $18.16B | $4.68B |
Dividend Yield | — | 1.26% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Manchester United PLC
Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.
Read more on MANU →
